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Abstract
Background: Several randomized controlled trials have compared different suture materials and
techniques for abdominal wall closure with respect to the incidence of incisional hernias after
midline laparotomy and shown that it remains, irrespective of the methods used, considerably high,
ranging from 9% to 20%. The development of improved suture materials which would reduce
postoperative complications may help to lower its frequency.
Design: This is a historically controlled, single-arm, multi-centre, prospective trial to evaluate the
safety of MonoMax® suture material for abdominal wall closure in 150 patients with primary
elective midline incisions. INSECT patients who underwent abdominal closure using Monoplus®
and PDS® will serve as historical control group. The incidences of wound infections and of burst
abdomen are defined as composite primary endpoints. Secondary endpoints are the frequency of
incisional hernias within one year after operation and safety. To ensure adequate comparability in
surgical performance and recruitment, the 4 largest centres of the INSECT-Trial will participate.
After hospital discharge, the investigators will examine the enrolled patients again at 30 days and
at 12 ± 1 months after surgery.
Conclusion: This historically controlled, single-arm, multi-centre, prospective ISSAAC trial aims
to assess whether the use of an ultra-long-lasting absorbable monofilament suture material is safe
and efficient.
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Background
Midline laparotomy is a standard method for gaining
access to the abdominal cavity. However, in spite of a
great number of different suture materials and techniques
being available to achieve closure of the abdominal wall,
the incidence of abdominal wall hernia remains high
(ranging from 9% to 20%) [1-3]. The latest data show that
52% of incisional hernias occur within 6 months postop-
eratively, 68% within one year and 79% within two years
after surgery [3,4]. They do not only require most often
surgery, but even after adequate treatment, they show
recurrence rates up to 45% [5]. Another complication of a
complex abdominal wall closure is a burst abdomen
occurring in 1% to 3% of the patients within the first days
after laparotomy [6-8].
Rationale
Various randomized controlled trials and four corre-
sponding meta-analyses reported in the literature have
compared different suture – slowly absorbable versus rap-
idly or non-absorbable – materials or different suture –
interrupted versus continuous running – techniques for
abdominal wall closure [9-14]. These studies suggest that,
using a running suture technique, slowly absorbable
monofilament sutures may be the best choice for abdom-
inal wall closure. As one possible reason for the still rele-
vant incidence of incisional hernias, experimental
research has demonstrated that, one year after a midline
laparotomy, the abdominal fascia retains only 70% of its
original strength, suggesting that adequate abdominal
wall closure preferably needs a longer-lasting supporting
suture [4]. Even though synthetic absorbable sutures such
as polyglactin, polyglycolic and polydioxanone are slowly
absorbable, they are fully absorbed after 70 to 180 days.
Therefore, an ultra-long-term absorbable suture material
may help to reduce the above mentioned postoperative
complications such as incisional hernia or burst abdo-
men.
Purpose
The ISSAAC-Trial, a prospective multi-centre historically
controlled trial, was designed to evaluate the clinical
safety and efficacy of MonoMax®, a new suture material.
MonoMax® is an ultra-long-lasting, absorbable, flexible
and elastic monofilament with superior initial strength
and predictable constant degradation rate. Compared to
other absorbable monofilament suture materials, Mono-
Max® shows superiority in knot and long-lasting linear
tensile strength retention and provides additional secu-
rity, indicating that MonoMax® might be very well suitable
for abdominal wall closure. To ensure optimal compara-
bility with the study population of the INSECT-Trial as
well as fast patient recruitment, only the four centres most
successful in recruiting patients for the INSECT-Trial will
enrol patients for the ISSAAC-Trial.
Methods/Design
Study objectives
The aim of the ISSAAC-Trial is to show the safety and effi-
cacy of MonoMax® suture material. To assess its safety,
parameters such as wound infections and re-operation
due to burst abdomen will be evaluated. It is expected that
the frequency of both parameters may be equal or lower
in the ISSAAC patient cohort than in the INSECT patient
cohort. To assess its efficacy, the frequency of abdominal
hernias at 12 ± 1 months after surgery is taken as parame-
ter and is also expected to may be equal or lower than in
the INSECT-Trial [15,16].
The hypothesis would be that that the frequency of
wound infection and of re-operation due to burst abdo-
men until day of discharge are equal or lower in the
patient cohort enrolled in the ISSAAC-Trial compared to
patients included in the INSECT-Trial.
For the ISSAAC-Trial, a standardized surgical technique of
abdominal wall closure with continuous monofilament
sutures is being used as it was in the INSECT-Trial. Thus,
the results obtained from both trials will be comparable.
To this end, only patients operated with the use of either
MonoPlus® or PDS® as suture material during the INSECT-
Trial will be included in the control group, excluding the
patients randomized to interrupted sutures.
The composite primary endpoints of the ISSAAC-Trial are
the frequency of wound infection, defined as redness,
wound dehiscence with secretion (putrid or caliginous,
smelly fluid) and/or microbiologic evidence of bacterial
contamination, and the frequency of re-operation due to
burst abdomen until day of discharge (see Table 1).
The secondary endpoints of the ISSAAC-Trial are the fre-
quency of abdominal hernias at 12 ± 1 months after sur-
gery, the frequency of wound-infection and complicated
wound healing at 30 days after surgery, and the length of
the hospital stay.
The incidence of incisional hernia within 12 ± 1 months
after the operation diagnosed by physical and ultrasound
examination is considered as secondary endpoint. A her-
nia is deemed present if the ultrasound examination
shows a fascial gap and a protruding sac and if confirmed
by the clinical examination. Assessment and documenta-
tion will be performed by a person who is familiar with
the examination of the abdominal wall, but not involved
in the surgical procedure. The ultrasound examination
will be carried out by an investigator who has at least 6
months training in this method.BMC Surgery 2008, 8:12 http://www.biomedcentral.com/1471-2482/8/12
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Ethics and informed consent
The final protocol was approved by the Ethics Committee
of the University of Heidelberg Medical School. Second-
ary approval was obtained from all local ethics commit-
tees responsible for the participating centres. All patients
eligible will be asked whether they are willing to partici-
pate in the trial and informed about the purpose of the
trial, the operative procedures as well as their options and
risks. Written informed consent will be obtained from all
patients participating in the trial.
Intervention
Surgical technique
The operation begins with a skin incision performed with
the electric cautery which penetrates through the subcuta-
neous layer. Next, the abdominal fascia is separated in the
midline line with the electric cautery. Then, the incision of
the peritoneum is made with the scissors and completed
with the electric cautery. The surgical procedure is carried
out in the usual fashion and according to local standards
regarding the indication for the intervention.
Starting either from the cranial end or from the caudal end
of the wound, the abdominal wall is closed by placing
four Mikulicz or equivalent clamps at the edges of the
abdominal fascia and a continuous all-layer suture using
two MonoMax® loops (USP1/Aesculap AG, Tuttlingen,
Germany). Before use, in order to avoid breakage of the
material, the monofilament suture MonoMax® has to be
stretched once by the assisting nurse/operation techni-
cian. The first stitch should be anchored cranially and cau-
dally of the incision. The distance to the edge of the fascia
and the distance between two stitches should not exceed
2 cm to 2.5 cm. After having closed half of the wound, the
surgeon cuts one end of the loop immediately below the
needle, passes it then from the opposite edge of the fascia
and ties both ends with at least four knots. He proceeds in
the same manner with the loop from the caudal end of the
wound which intersects the other loop at the middle of
the incision, both sutures lines overlapping at least 2 cm.
For every patient two loops must be used, irrespective of
the length of the wound. After completion of the fascia
closure, the loop is cut directly underneath the needle.
No subcutaneous or drainage is inserted. The skin is
closed with skin clips or interrupted sutures with monofil-
ament non-absorbable sutures. At the end of the interven-
tion, the length of the incision is measured in cm.
During the first investigator meeting (November 22th,
2007, Stuttgart, Germany), all participating trial centres
were retrained in the required technique using abdominal
wall models of mini-pigs and provided with a CD-ROM
demonstrating the required surgical technique. Further-
more, they have continuous access to technical support by
suture product specialists from Aesculap AG for all suture-
related issues and questions.
Postoperative intervention
After discharge from the hospital, the investigators will
examine the patients at 30 days and at 12 ± 1 months after
surgery. All complications leading to re-operation due to
burst abdomen, wound infection and complicated wound
healing will be documented within 30 days after surgery.
At one year postoperatively, the incidence of incisional
hernias will be recorded by physical and abdominal ultra-
sound examination. In total, the trial will last 12 ± 1
months for each patient (see Table 2).
Clinical sites
The selected sites were most successful in enrolling
patients for the INSECT-Trial. Therefore four centres
located in Germany will recruit 150 patients (for all inclu-
sion and exclusion criteria see Table 3). All investigators
are hospital-based general surgeons.
Safety aspects
The term "adverse event" covers any sign, symptom, syn-
drome, illness that appear or worsen in a subject during
the period of observation in the clinical trial and that may
Table 1: Definition of complications
Complication Definition
Burst abdomen Postoperatively missing continuity of the abdominal fascia 
in combination with a wound dehiscence and consecutive 
relapse operation.
Wound infection Redness, wound dehiscence with secretion either of putrid 
or caliginous, smelly fluid and/or mircobiologic evidence of 
bacterial contamination.
Incisional hernia A hernia is present if the ultrasound shows a fascial gap 
and a protruding hernial sac and the clinical exam is 
consistent with a hernia.
Complicated wound healing Incision has not completely closed. Necrosis of the wound 
edge or primary or secondary dehiscence occurs. Formation 
of seroma, fistula, necrosis, and bleeding.BMC Surgery 2008, 8:12 http://www.biomedcentral.com/1471-2482/8/12
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impair the well-being of the subject. The term also covers
laboratory findings of other diagnostic procedures that are
considered to be clinically relevant.
A "serious adverse event" is any adverse event occurring at
any time during the period of observation that results in
death, is immediately life-threatening, requires or pro-
longs hospitalization, results in persistent or significant
disability or incapacity.
All adverse events occurring in the abdominal region
between the beginning of wound closure and the last visit
of the patient at 12 months postoperatively must be doc-
umented on the appropriate AE form in the CRF, exclud-
ing adverse events that affect other body systems as they
Table 2: Flow Chart ISSAAC Trial
Visit 1 
(Screening)
Visit 2 
(day 0)
Visit 3 
(day 2 ± 1)
Visit 4 
(day of discharge 
or the day before)
Visit 5 
(day 30 ± 5)
Visit 6 
(12 ± 1 months
post surgery)
Informed consent X
Demographic data* X
BMI X
Smoker/non-smoker X
Inclusion/exclusion X
Medical history X
Physical examination X X1) X1) X1) X2)
Reason for surgery X
Surgery X
Board certified surgeon X
Deviations from surgical procedure as described in 
protocol
X
Ultrasound of the abdominal wall X
Abdominal Adverse Event/Serious Adverse Event X X X X X
Re-operation due to burst abdomen necessary? X X X X
Wound infection X X X
discharge X
1) of the abdomen and the laparotomy wound
2) of the abdomen
* date of birth, gender, weight, height
Table 3: Eligibility Criteria
Inclusion criteria Exclusion criteria
Age equal or greater than 18 years Peritonitis
Expected survival time more than 12 months Emergency surgery
Patients undergoing primary and elective midline 
laparotomy (patients with prior laparoscopy or 
abdominal operation via paramedian incision (e.g. 
appendectomy) may be included in the trial
Coagulopathy (= A group of disorders of the blood clotting (coagulation) system in 
which bleeding is prolonged and excessive with abnormal values in the blood laboratory
• Lack of compliance
BMI < 35 Severe psychiatric or neurologic disease
Expected length of skin incision > 15 cm Lack of informed consent
Participation in another intervention with interference of intervention and outcome of 
this trial
Drug- and/or alcohol-abuse according to local standard
Current immunosuppressive therapy (more than 40 mg of a corticoid per days or 
azathioprin
Chemotherapy within two 2 before operation
Radiotherapy of the abdomen completed less than 8 weeks before operation
Inability to understand and to follow the instructions given by the investigator 
(e.g. insufficient command of language, dementia, lack of time)
Pregnant or breast-feeding woman (according to information given by the patient)
Patients who have been committed to an institution by virtue of an order issued either 
by the courts or by an authorityBMC Surgery 2008, 8:12 http://www.biomedcentral.com/1471-2482/8/12
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are not related to the intervention. Complications such as
burst abdomen, wound infection, complicated wound
healing, presence of incisional hernia are defined as
adverse events (for definition see Table 1). Re-operation
due to burst abdomen is classified as a serious adverse
event.
Analysis of safety related data performed with respect to:
- Frequency of SAEs
- Frequency of SAEs stratified by severity
- Frequency of SAEs stratified by causality.
The sponsor will notify the competent authorities, ethics
committees and all investigators concerned of unexpected
SAEs and unexpected adverse device effects in line with
applicable regulatory requirements.
As the adverse event definition used in the INSECT-Trial
was broader, two surgeons will independently select from
this trial's list of adverse events the adverse events to be
taken for comparison in the present trial in accordance
with the established definition.
Statistical considerations and sample size estimation
Patients are included for primary analysis if information
about complications is available up to the day of dis-
charge. Non-compliant and compliant patients will be
compared with respect to age and sex distribution.
About 80 patients from the INSECT-Trial will serve as con-
trol group. Using the 1:4 rule, up to 320 patients could be
collected in a sensible manner. Within a reasonable time-
frame of 1 year, 150 patients could be enrolled into the
ISSAAC-Trial. Assuming a drop-out rate of 7%, 140
patients could be subjected to an analysis with respect to
the primary endpoints. This would be sufficient to con-
struct a 90% confidence interval around the estimate that
would not cover the value of 25% with a power of 10%
when the true event rate is at 15%.
It is expected that the historical control group will com-
prise about 130 patients who had been enrolled into the
INSECT-Trial. To make the comparison with the historical
control group as meaningful as possible (using an "infor-
mation per patient" metric), the size of the MonoMax®
group should not exceed the size of the control group by
too much und has been accordingly established at 150
patients, allowing for 10 drop-outs.
Each participating centre should add at least 1/4 to the
patients it had recruited during the INSECT-Trial, e.g. Mar-
burg at least 7 patients and the other three at least 10
patients each. In order to avoid a centre effect, no partici-
pating hospital should include more than 80 patients.
The level of significance for the confidence intervals is set
at 95 and 90% in order to perform a one-sided test of sig-
nificance against the 25% event rate stated in the null
hypothesis.
Trial organization, coordination and registration
The ISSAAC-Trial is initiated and sponsored by BBraun
Aesculap and conducted by Aesculap AG in cooperation
with the Coordinating Center for Clinical Trials (KKS) in
Heidelberg. The KKS Heidelberg is responsible for moni-
toring, biometrics, database, and project management.
The Sponsor's role is limited to supplying the participat-
ing trial centre with the suture material and surgical sup-
port. It is not involved in the data base management. It
has taken out an insurance policy to cover all patients tak-
ing part in the trial.
The trial is coordinated by the Coordinating Center for
Clinical Trials in cooperation with BBraun Aesculap. Both
were responsible for management and registration (Iden-
tifier Number NCT 0005725079, http://www.clinicaltri
als.gov) and all trial related meetings.
The trial is performed according to the Declaration of Hel-
sinki in its current German version, the national medical
device law and the guidelines for Good Clinical Practice
(GCP), as applicable.
On-site monitoring
Authorized, qualified representatives of the Sponsor will
visit the investigational sites at regular intervals to verify
adherence to protocol and local legal requirements, per-
form source data verification and assist the Investigator in
his trial related activities.
During recruitment of patients, the participating study
centres will be monitored according to Good Clinical
Practice (GCP) guidelines. A monitor from the Coordinat-
ing Center for Clinical Trials will audit the data.
Data management and quality assurance
Data is entered in prepared electronic CRFs which form a
front end to a database. The Clinical Database Manage-
ment System MACRO (Infermed Ltd., London, UK) is
used for planning and entering data into the database.
Range and plausibility checks are programmed into the
database. An audit trail ensures that original entries
remain accessible after correction. Data entry is be per-
formed by personnel trained on the use of the system dur-
ing the monitor's initiation visit.BMC Surgery 2008, 8:12 http://www.biomedcentral.com/1471-2482/8/12
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Data reported on the CRF derived from source documents
should be consistent with the source documents or the
discrepancies should be explained. Within two weeks after
completion for each patient, the Investigator should con-
firm that he has completed, signed the CRFs and made
them available for full inspection by the clinical monitor.
Enrolment must be reported immediately by the investi-
gators by fax on prepared forms directly to the KKS.
Closing of the clinical data and follow-up database
The clinical database, including all information until 12
months postoperatively, will be closed after the 12
months follow-up visit of the last patient enrolled into the
ISSAAC-Trial. There will be an interim analysis after the 30
days follow-up visit of the last enrolled patient which
includes the combined primary endpoint and the second-
ary endpoints, i.e. wound infections and wound healing
disorders after 30 days of surgery. The results of the other
secondary endpoint, incisional hernia at 12 months post-
operatively, will be evaluated accordingly.
Current status and planning
The study protocol for this trial was completed in August
2007. A first investigator meeting was held on 22th
November, 2007 in Stuttgart, Germany. Preparation of all
study related-material was brought to an end in Novem-
ber 2007. In December 2007, following completion of
contracts and approval of local ethics committees, all cen-
tres were initiated, the first patient being recruited on the
5th December 2007. Currently all 4 centres are recruiting
patients with a goal of 150 patients. Assuming an overall
enrolment of 25 patients per month, the end of recruit-
ment is expected for June 2008.
Discussion
An "ideal" suture material would help to prevent the
occurrence of incisional hernias and other complications
such as wound infections, wound pain and suture sinus to
a minimum. Although various randomized controlled
clinical trials have been reported in the literature address-
ing the use of different suture materials and techniques for
abdominal wall closure after midline laparotomy, no
ideal combination of suture material or technique has
been found so far [9,12-14,17].
Several of these trials compared slowly-absorbable versus
fast-absorbable or non-absorbable suture materials and
others interrupted versus continuous running suture tech-
niques [9,12-14,16-18]. They reported a significant higher
incidence of wound pain and suture sinus formation
where non-absorbable suture material was used. The
results also showed that closing the abdominal wall clo-
sure with continuous rapidly absorbable suture material
was correlated with a significantly higher occurrence of
incisional hernias compared to closure by continuous
slowly-absorbable or non-absorbable suture material
[12,22]. However, no statistically significant differences in
outcome features of wound dehiscence and wound infec-
tion were found when various suture materials were com-
pared [13,14]. It has been suggested a correlation between
postoperative wound infection and development of inci-
sional hernias [17]. Thus, the prevention of wound infec-
tion may be more important in avoiding incisional
hernias than the kind of suture material or the type of clo-
sure technique [19-21].
Most authors suggest that a slowly absorbable monofila-
ment suture material is superior to a non-absorbable
suture material for closure of the abdominal wall. Further-
more, the presumably ideal suture technique appears to
be a mass closure using a continuous running suture tech-
nique with an adequate suture length to wound length
ratio of at least 4:1 [14,22,23]. However, there is no stand-
ard technique generally accepted as best or rather safest
for closing the abdominal wall after primary midline
laparotomy. This was one of the reasons to design and
conduct the INSECT-Trial with the aim to answer the
question of the best method to perform this intervention
[16]. Using three different closure methods, the frequency
of incisional hernias within one year postoperatively was
compared as primary endpoint.
Synthetic absorbable sutures which have become availa-
ble over the last decade have the advantage that they are
degraded by the body system and fully absorbed within
70 to 180 days. However, they lose 50% of their tensile
strength already after 14 to 30 days [24]. Therefore, they
may be not the optimal suture material for abdominal
wall closure. The ISSAAC-Trial was designed to investigate
whether the use of an ultra-long-lasting absorbable
monofilament suture material is safe and prevents the
occurrence of incisional hernias after primary midline
laparotomy.
Several potential risk factors may have an influence on the
occurrence of incisional hernias such as complicated
wound healing, wound infections, obesity, chronic bron-
chitis or diabetes mellitus [4,25-28]. However, wound
infection remains the most significant early postoperative
complication in 3 to 21% of patients undergoing midline
laparotomy [4,19,21,29,30]. Thus, the prevention of
wound healing complications should reduce substantially
the incidence of incisional hernias. Studies comparing
slowly absorbable versus rapidly absorbable suture mate-
rial for closing abdominal wounds showed that none of
the suture materials provided satisfactory results in pre-
venting wound healing complications. In order to evalu-
ate the safety of MonoMax®, we chose as primary
combined endpoint for our trial the frequency of woundBMC Surgery 2008, 8:12 http://www.biomedcentral.com/1471-2482/8/12
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infections, the frequency of complicated wound healing
and the frequency of re-operation due to burst abdomen
until day of discharge and defined as secondary endpoints
the frequency of wound infection and healing disorders at
30 days after surgery. Since the literature shows that 50 to
70% of incisional hernias develop within one year post-
operatively, we chose an additional secondary endpoint,
that is the frequency of incisional hernia one year after
surgery, as efficacy variable [4].
In the ISSAAC-Trial, a highly standardized surgical proce-
dure will be used along with the suturing technique
already used in the INSECT-Trial. Thus, it is reasonable to
compare the results from the present trial with the data
already collected during the earlier study. Because ISSAAC
uses continuous monofilament suturing material, only
patients enrolled in the INSECT-Trial who underwent the
same treatment with MonoPlus® and PDS® will serve as
control group.
Conclusion
The ISSAAC trial is a historically controlled, single arm,
multi-centre, prospective surgical trial to evaluate the
safety and efficacy of a long-lasting suture material, Mon-
oMax®, for abdominal wall closure after primary midline
laparotomy. As clinical relevant conclusion, the ISSAAC-
Trial aims to find out whether the use of MonoMax® will
reduce the rate of wound infections and subsequently
lower the incidence of incisional hernias.
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